Open AccessSwitching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study
Author(s) -
Debbie Hagins,
Princy Kumar,
Michael S. Saag,
Anson K Wurapa,
Indira Brar,
Daniel Berger,
Olayemi Osiyemi,
Corrilynn Olesky Hileman,
Moti Ramgopal,
Cheryl McDonald,
Christiana Blair,
Kristen Andreatta,
Sean E Collins,
Diana M. Brainard,
Hal Martin,
Braave Investigators
Publication year - 2021
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000002731
Subject(s) - tenofovir alafenamide , emtricitabine , medicine , resistance mutation , dolutegravir , regimen , randomized controlled trial , clinical endpoint , confidence interval , adverse effect , gastroenterology , virology , human immunodeficiency virus (hiv) , viral load , biology , reverse transcriptase , antiretroviral therapy , rna , biochemistry , gene
With the highest rates of HIV/AIDS in the United States, Black Americans are still underrepresented in HIV medical research.